Trial · NCT05323656
Outcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Percentage Change in Tumour Size | Baseline to at least 15 weeks and up to 51 weeks | Full Analysis Set | Percentage change from baseline | LEAST_SQUARES_MEAN |
| SECONDARY | Progression Free Survival (PFS) | Baseline up to approximately 21 months | Full Analysis Set | days | MEDIAN |
| SECONDARY | Change From Baseline in Cancer-associated Fibroblasts (CAFs) Level in Tumour Tissue | Baseline up to approximately 9 weeks | Full Analysis Set | % positivity of tumour stromal component | MEAN |
| SECONDARY | Change From Baseline in the Number of Cluster of Differentiation 8 (CD8+) Tumour Infiltrating Lymphocytes (TILs) in Tumour Tissue | Baseline up to approximately 9 weeks | Full Analysis Set) | cells/High Power Field (HPF) | MEAN |
| SECONDARY | Change From Baseline in the Number of Regulatory T-cells in Tumour Tissue | Baseline up to approximately 9 weeks | cells/High Power Field (HPF) | MEAN | |
| SECONDARY | Overall Response Rate (ORR) | Baseline up to approximately 12 months | Full Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of Response (DoR) | Baseline up to approximately 12 months | Full Analysis Set | days | NUMBER |
| SECONDARY | Disease Control Rate (DCR) | Baseline up to approximately 12 months | Full Analysis Set | percentage of participants | NUMBER |
| SECONDARY | Overall Survival (OS) | Baseline up to 12 months | Full Analysis Set | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Adverse Events (AEs) | Baseline up to approximately 21 months | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Adverse Events of Special Interest (AESI) | Baseline up to approximately 21 months | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Levels of Programmed Death-ligand 1 (PD-L1) Expression in Tumour Tissue | Baseline up to approximately 9 weeks | Full Analysis Set | ratio | MEAN |
| SECONDARY | Change From Baseline in CAFs Cell Type Abundance Based on Gene Expression Profiles | Baseline up to approximately 9 weeks | Full Analysis Set with paired observations | CIBERSORTx Absolute Abundance ratio | MEAN |
| SECONDARY | Change From Baseline in CD8+ TILs Cell Type Abundance Based on Gene Expression Profiles | Baseline up to approximately 9 weeks | Full Analysis Set with paired observations | CIBERSORTx Absolute Abundance ratio | MEAN |
| SECONDARY | Change From Baseline in Regulatory T-cell Abundance Based on Gene Expression Profiles | Baseline up to approximately 9 weeks | Full Analysis Set with paired observations | CIBERSORTx Absolute Abundance ratio | MEAN |
| SECONDARY | Area Under The Concentration-time Curve Over a 24-hour Period at Steady State (AUC[0-24]-ss) of Setanaxib | Baseline, Week 3, week 9, week 24, week 51 | PK analysis set | ug*h*mL-¹ | GEOMETRIC_MEAN |
| SECONDARY | Area Under The Concentration-time Curve Over a 24-hour Period at Steady State (AUC24-ss) of GKT138184 | Baseline, Week 3, week 9, week 24, week 51 | PK analysis set | ug*h*mL-¹ | GEOMETRIC_MEAN |
| SECONDARY | Minimum Plasma Concentration at Steady State (Cmax-ss) of Setanaxib | Baseline, Week 3, week 9, week 24, week 51 | PK analysis set | ug*mL-¹ | GEOMETRIC_MEAN |
| SECONDARY | Minimum Plasma Concentration at Steady State (Cmin-ss) of GKT138184 | Baseline, Week 3, week 9, week 24, week 51 | PK analysis set | ug*mL-¹ | GEOMETRIC_MEAN |
| SECONDARY | Maximum Plasma Concentration at Steady State (Cmax-ss) of Setanaxib | Baseline, Week 3, week 9, week 24, week 51 | PK analysis set | ug*mL-¹ | GEOMETRIC_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/outcomes